Search Results - "Ruff, Dustin D."

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response by Newcorn, Jeffrey H., Kratochvil, Christopher J., Allen, Albert J., Casat, Charles D., Ruff, Dustin D., Moore, Rodney J., Michelson, David

“…Objective: Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral…”
Get full text

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study by Lipton, Richard B., Lombard, Louise, Ruff, Dustin D., Krege, John H., Loo, Li Shen, Buchanan, Andrew, Melby, Thomas E., Buse, Dawn C.

“…Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT 1F receptor agonist…”
Get full text

CYP2D6 and Clinical Response to Atomoxetine in Children and Adolescents With ADHD by MICHELSON, DAVID, M.D, READ, HOLLY A., M.D., Ph.D, RUFF, DUSTIN D., Ph.D, WITCHER, JENNIFER, Ph.D, ZHANG, SHUYU, M.S, McCRACKEN, JAMES, M.D

“…ABSTRACT Background Atomoxetine, a selective norepinephrine reuptake inhibitor effective in the treatment of attention-deficit/hyperactivity disorder (ADHD),…”
Get full text

A Pilot Study Using a Web Survey to Identify Characteristics That Influence Hypogonadal Men to Initiate Testosterone Replacement Therapy by Rosen, Raymond C., Seftel, Allen D., Ruff, Dustin D., Muram, David

“…Men with hypogonadism (HG) who choose testosterone replacement therapy (TRT) may have distinct characteristics that provide insight as to why they may/may not…”
Get full text

Onset of Response with Duloxetine Treatment in Patients with Osteoarthritis Knee Pain and Chronic Low Back Pain: A Post Hoc Analysis of Placebo-Controlled Trials by Williamson, Owen D., MBBS, Schroer, Melissa, MD, Ruff, Dustin D., PhD, Ahl, Jonna, PhD, Margherita, Anthony, MD, Sagman, Doron, MD, Wohlreich, Madelaine M., MD

“…Abstract Background Knowing when to change pain-medication strategy is not well researched and remains a gap in treating chronic pain. Objective Our aim was to…”
Get full text

The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel by Burns, Patrick R., Kim, Edward D., Ruff, Dustin D., Seftel, Allen D.

“…This study evaluated the effect of axillary administration of a 2% testosterone solution (Axiron®) in hypogonadal (HGN) men who had had a suboptimal response…”
Get full text

Monitoring Pregnancies Exposed to Galcanezumab for Migraine in a United States Administrative Claims Database by Hoffman, Sarah R., Mawanda, Francis, Crowe, Christopher L., Ruff, Dustin D., Lanes, Stephan, Schroeder, Krista

“…ABSTRACT Purpose Galcanezumab is a calcitonin gene‐related peptide monoclonal antibody indicated for migraine prevention in adults. Due to the long half‐life…”
Get full text

High-Dose Atomoxetine Treatment of ADHD in Youths With Limited Response to Standard Doses by KRATOCHVIL, CHRISTOPHER J., M.D, MICHELSON, DAVID, M.D, NEWCORN, JEFFREY H., M.D, WEISS, MARGARET D., M.D., Ph.D, BUSNER, JOAN, Ph.D, MOORE, RODNEY J., Ph.D, RUFF, DUSTIN D., Ph.D, RAMSEY, JANET, M.S., M.P.H, DICKSON, RUTH, M.D, TURGAY, ATILLA, M.D, SAYLOR, KEITH E., Ph.D, LUBER, STEPHEN, M.D, VAUGHAN, BRIGETTE, M.S.N., A.P.R.N, ALLEN, ALBERT J., M.D., Ph.D

“…ABSTRACT Objective: To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD)…”
Get full text

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine by Ford, Janet H., Kurth, Tobias, Starling, Amaal J., Ayer, David W., Wietecha, Linda A., Port, Martha D., Rettiganti, Mallikarjuna, Ruff, Dustin D.

“…Objective This post hoc study investigated the relationship between patient response in terms of migraine headache day reduction and patient‐reported outcomes…”
Get full text

Prospective Case-crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy and Phosphodiesterase Type 5 Inhibitor Exposure by Flahavan, Evelyn M, Li, Hu, Gupte-Singh, Komal, Rizk, Rosemary T, Ruff, Dustin D, Francis, Jennie Lin, Kinchen, Kraig S

“…Objective To evaluate the association between intermittent phosphodiesterase type 5 inhibitor (PDE5i) exposure and risk of acute nonarteritic anterior ischemic…”
Get full text

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine by Ford, Janet H, Foster, Shonda A, Stauffer, Virginia L, Ruff, Dustin D, Aurora, Sheena K, Versijpt, Jan

“…Effects of galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, on patient satisfaction, health care resource utilization (HCRU), and…”
Get full text

Atomoxetine Tolerability in Pediatric and Adult Patients Receiving Different Dosing Strategies by WIETECHA, Linda A, RUFF, Dustin D, ALLEN, Albert J, GREENHILL, Laurence L, NEWCORN, Jeffrey H

“…Examine how different dosing schedules and recent stimulant therapy effect incidence, time to onset, and duration of common treatment-emergent adverse events…”
Get full text

Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study by Clemow, David B, Mason, Oren W, Sarkis, Elias H, Ruff, Dustin D, Berman, Brad D, Donnelly, Craig L, Robb, Adelaide S, Holland, Donna S, Schuh, Kory J, Barnes, Janet M, Araujo, Andre B

“…To analyze Clinical Global Impression-Severity (CGI-S) in ADHD patients treated with atomoxetine (ATX) monotherapy versus ATX combination therapy with another…”
Get more information

Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder by Newcorn, Jeffrey H, Michelson, David, Kratochvil, Christopher J, Allen, Albert J, Ruff, Dustin D, Moore, Rodney J, Atomoxetine Low-dose Study Group

“…Data from acute studies of atomoxetine in patients with attention-deficit/hyperactivity disorder suggest that a dose of approximately 1.2 mg/kg per day is…”
Get full text

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment by Spencer, Thomas J, Kratochvil, Christopher J, Sangal, R Bart, Saylor, Keith E, Bailey, Charles E, Dunn, David W, Geller, Daniel A, Casat, Charles D, Lipetz, Robert S, Jain, Rakesh, Newcorn, Jeffrey H, Ruff, Dustin D, Feldman, Peter D, Furr, Amanda J, Allen, Albert J

“…To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an…”
Get more information

Atomoxetine and tics in ADHD by Feldman, Peter D, Ruff, Dustin D, Allen, Albert J

Get more information

Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies (S20.004) by Zhang, Qi, Ruff, Dustin D., Pearlman, Eric M., Govindan, Sriram, Aurora, Sheena K.

“…Abstract only…”
Get full text

CYP2D60 and Clinical Response to Atomoxetine in Children and Adolescents with ADHD by Michelson, David, Read, Holly A, Ruff, Dustin D, Witcher, Jennifer, Zhang, Shuyu, McCracken, James

“…Background: Atomoxetine, a selective norepinephrine reuptake inhibitor effective in the treatment of attention-deficit/hyperactivity disorder (ADHD), is…”
Get full text

Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.(Clinical report) by Newcorn, Jeffrey H, Michelson, David, Kratochvil, Christopher J, Allen, Albert J, Ruff, Dustin D, Moore, Rodney J

“…OBJECTIVE. Data from acute studies of atomoxetine in patients with attention-deficit/hyperactivity disorder suggest that a dose of ~1.2 mg/kg per day is…”
Get full text